Compare KLA Corp. (KLAC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Sanofi SA — how do they compare? KLA Corp. trades at $208.99 (market cap $272.09B), while Sanofi SA trades at $43.91 (market cap $104.30B). The key difference: KLA Corp. is far larger — about 2.6× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| KLAC | SNY | |
|---|---|---|
Market Cap | $272.09B | $104.30B |
Sector | Technology | Health |
52-Week High | $301.71 | $52.34 |
52-Week Low | $84.39 | $41.33 |
Enterprise Value | $273.34B | $124.19B |
Dividend Yield | 0.44% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $209.37, up 4.44% today, with a bullish technical signal and strong support near $206. Recent earnings beats and a 63.63% analyst buy rating reflect robust fundamentals, including a 35.57% net margin and 87.5% ROE. The stock split and dividend hikes signal confidence, while AI-driven semiconductor demand supports growth.
Outlook is positive with a $246.93 consensus price target, though high valuation ratios (P/E 56.9) and sector volatility pose risks. Revenue growth to $13.6B in 2026 and operational cash flow strength underpin opportunities, but investors should monitor margin pressures and cyclical chip demand.
SNY trades at $43.78, up 0.51% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales outlook. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%. Key growth driver Dupixent surpassed €5 billion in quarterly sales, supporting positive sentiment amid pipeline adjustments under new CEO Belen Garijo.
SNY presents a mixed outlook with solid fundamentals and recent earnings beats offset by pipeline setbacks and competitive risks. The stock's valuation metrics, including a P/E of 23.38 and P/S of 1.88, appear reasonable relative to peers. However, investors face risks from biosimilar threats to Dupixent post-2031 and regulatory scrutiny. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism for upside potential driven by execution on new drug launches and cost discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
